StockWatch
·
ADITYA INFOTECH LTD · QQ2 FY-2027 · THE CALL

Strong growth, margin discipline. Guidance raised on revenue, hedged on H2 costs.

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsCPPLUSAditya Infotech Ltd13 Nov 2026 · 6 min read
Verdict

Buy

confidence 7/10

Credibility

Grade A

Q2 beat on revenue (1,746 vs implied ~1.7Cr), EBITDA margin delivered 17.6% vs guided 14-15% range, PAT 185.5 Cr. Management has track record of 'always over-delivered from guidance'.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Very Optimistic

multi-year

Aditya has delivered a blockbuster quarter (+89.9% revenue, +165% PAT) and raised full-year revenue guidance. Market share momentum is real (42% to 45% by year-end), backed by capacity expansion, component localization, and a three-tier brand strategy. However, management is deliberately holding EBITDA margin at 14-15% to protect share in a volatile cost environment; H2 will see margin compression to ~13%. The risk is if SOC/memory costs don't stabilize as anticipated.

₹1746 Cr

Revenue · +89.9% YoY

₹185.5 Cr

Reported PAT · +165.1% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Revenue 1,746 Cr, up 89.9% YoY

MET

Delivered 1,746 Cr, 89.9% YoY growth (H1 3,148 Cr up 89.7%)

PAT 185.5 Cr (after 34.4 Cr fire insurance claim, PAT before exceptional 220 Cr)

MET

Delivered 185.5 Cr; prior Q2 ~71 Cr → implies 165.1% YoY on reported basis, 214% on pre-exceptional

EBITDA margin 17.6% in Q2, gross margin 30% flat YoY, up 374 bps H1

MET

H1 gross margin 30.4% confirmed YoY; Q2 margin 30% flat QoQ; EBITDA 307 Cr on 1,746 Cr = 17.6%

CP PLUS contributed 88% of Q2 revenue (up from 86% prior year)

MET

Management stated explicitly; implies non-CP PLUS ~₹209 Cr = growing faster on lower base

FY27 full-year revenue guidance raised to ₹6.5-6.8 Cr from ₹6.0-6.5 Cr

MET

MD: 'Revenue, we are raising it to INR 6,500 crores, INR 6,800 crores, up from INR 6,000 crores'

EBITDA margin 14%-15% maintained; H2 will normalize lower due to SOC/memory volatility

MET

H1 delivered 16.3%; if FY27 is ₹6,650 Cr (midpoint) at 14.5%, H2 EBITDA ~449 Cr on 3,502 Cr = 12.8%

Earnings quality

What changed since the last call

Deltas vs. the prior call

Revenue guidance raised

Upgrade

Prior ₹6.0-6.5 Cr → now ₹6.5-6.8 Cr (54-61% YoY growth). Response to strong H1 momentum (₹3,148 Cr) and market share gains (42% of ~₹7.5Cr market).

PAT margin guidance raised

Upgrade

Now targeting 9-10% for FY27, vs. prior implied ~8%. Reflects pricing discipline & volume operating leverage. H1 delivered 11.5%, so second half will pull down to ~7-8%.

EBITDA margin guidance maintained

Neutral

Reaffirmed 14-15% despite H1 delivery of 16.3%. Management explicitly citing SOC/memory cost volatility risk and competitive positioning strategy (prioritizing share over margin in H2).

Market share target unchanged but quantified

Neutral

43-45% by end FY27 (from 30% at IPO, 42% now). Not a new target, but reaffirmed & narrowed range signals high confidence.

Capacity expansion plan firmed

Upgrade

₹650 Cr CapEx approved for doubling by late FY2029-early FY2030. Kadapa phase 3 + Greater Noida facility. Housing/cable/lens plants in detailed execution (house plant Q4 trials underway).

The Q&A

Analysts pressed on margin bridge (Dhruv Jain: if H1 is exceptional at 16.3%, how does H2 average to 14-15%? Answer: SOC/memory cost inflation → management conceded 13% likely for H2). Rahul Agarwal challenged how management sustains 54-61% growth if pricing hikes are exhausted; Anup acknowledged it's 'unit-growth driven' not price-led forward. No analyst directly challenged the guidance, suggesting acceptance of the story. Tone: analytical, not hostile; management held firm on margin strategy but conceded cost headwinds real.

The exchanges that mattered

Margin bridge and pricing — Dhruv Jain, Ambit Capital

Answered

Anup Nair: We are being prudent and maintaining margin cushion given SOC/memory volatility. H2 will normalize lower due to input cost environment. We want to ensure market share growth continues while protecting margins.

Backward integration timing — Dhruv Jain, Ambit Capital

Answered

Anup Nair: Housing plant goes live in Q4, cable plant in Q4 FY27. Full benefits accrue in next financial year (FY28) as volume flows through.

Competitive moat and STOC — Anuj Kashyap, A3 Capital

Partial

Aditya Khemka: Government taking strict stance on trusted supply chains from land-border countries. No company from border nations certified yet. Government policy still evolving. We're the only certified Indian brand manufacturing with STOC standards met.

Market share and competitive pressure — Anuj Kashyap, A3 Capital

Answered

Anup Nair: New entrants not showing significant traction on ground yet. We're monitoring closely. Guidance 43-45% market share by year-end reflects our competitive positioning. We have deepest localization, field teams, and brand trust.

EYRA and NEXIVUE brand traction — Nikhil, Investec

Partial

Anup Nair: EYRA will hit market by end-Nov/Dec. NEXIVUE launched April, seeing significant movement already. Both are early-stage. Pricing is entry-level to attack unorganized segment.

BLUE acquisition strategic logic — Manan Shah, ICICI Securities

Answered

Anup Nair: BLUE is tech-led, not revenue accretive in short term. Part of CP PLUS 2.0 strategy to add cloud storage and AI analytics to camera platform. Impact longer-term in services revenue, not cameras.

Export market entry — Manan Shah, ICICI Securities

Partial

Anup Nair: 18-24 month timeline to enter exports. Markets like China-plus strategy initially (not naming them yet). Products will be CP PLUS PRO or entry-level depending on market fit. R&D office in Taiwan, testing now.

Revenue mix shift to solutions — Santosh Seshadri, Avendus Spark

Partial

Anup Nair: Not a shift away; an add-on. Recurring revenue + products exports will both flow in. Cloud storage and AI analytics pricing to be built as we scale capabilities. Still early on specifics.

Growth rate and margin sustainability — Rahul Agarwal, Ikigai Asset

Answered

Anup Nair: Unit CAGR estimated 18-20% across industry. Price hikes mostly done (Q1 saw 10-20%, targeting 25% full-year). Going forward, growth will be volume-driven. Too many variables on cost side to model further price increases.

CapEx timeline and payoff — Rahul Agarwal, Ikigai Asset

Answered

Anup Nair: Total ~₹650 Cr planned to double capacity by late FY2029-early FY2030. Kadapa phase 3 + Greater Noida + housing/cable/lens plants included. Housing plant trials Q4; commercial production Q1 FY28.

EYRA/NEXIVUE contribution and dealer channel — Aniruddha Joshi, ICICI Securities

Partial

Aditya Khemka: 30,000-35,000 installer network across India. CP PLUS is de facto standard in most shops already. EYRA/NEXIVUE targeting to expand to 50%+ outlets by attacking unorganized side. TAM expansion is unorganized → organized shift.

Receivables and working capital cycle — Nikhil, Investec

Answered

Anup Nair: Receivables improved to 87 days in Q2 (from 93 in Q1, 105 a year ago). Same across all brands due to supply discipline. Cash flow grows at 90% is mostly going into growth; fairly comfortable with current WC levels.

Guidance

Forward guidance and management's confidence

FY27: ₹6,500–₹6,800 Cr (54–61% YoY growth)

High

Raised from prior ₹6,000–₹6,500 Cr. H1 delivery of ₹3,148 Cr (89.7% growth) and market share momentum support upper range. Assumes continued pricing discipline + volume growth.

EBITDA margin: 14%–15% FY27 (maintained)

High

Reaffirmed despite H1 delivery of 16.3%, indicating deliberate caution on H2 due to SOC/memory cost volatility. Management prioritizing market share protection over margin expansion.

PAT margin: 9%–10% FY27 (raised)

Medium

Upgraded from prior implied ~8%. H1 delivered 11.5% (362 Cr / 3,148 Cr), but lower finance cost post-QIP repayment will support H2. Backward integration benefits to accrue FY28 onward.

₹650 Cr total CapEx over 2–3 years (FY2027–FY2029)

High

Capacity doubling via Kadapa phase 3 + Greater Noida facility. Housing enclosure plant trials Q4 FY27, commercial Q1 FY28. Lens plant 2M lenses/month capacity. Funded from operations and QIP proceeds.

Risks the call surfaced

Ranked by how much they should concern a holder

Input cost volatility

High

SOC and DRAM costs are volatile; management flagging this as reason for guided margin compression (H1 16.3% → H2 ~13%). If prices spike further, could push margins below 14% FY27 guidance.

Competitive pressure

Medium

40+ new STOC-certified brands entering market; Chinese/US competitors applying for STOC certifications (though none certified from border nations yet). Unorganized sector fragmented with many players.

Execution risk on CapEx

Medium

Kadapa phase 3 + Greater Noida facility + housing/cable/lens plants are multi-year build. Construction delays, cost overruns, or talent shortages could push capacity online later than planned, limiting growth in FY28–29.

EYRA and NEXIVUE brand ramp uncertainty

Medium

EYRA just hitting market (end-Nov/Dec); NEXIVUE launched April seeing 'significant movement' but not quantified. Risk that entry/mid-market segments remain captured by unorganized players or don't convert to formal products.

Export market timing and execution

Medium

Export entry timefame is long (mid-2027 onward). Strategy still vague ('China-plus'; geographies not named yet). Risk that execution slips, or that initial export revenue is immaterial and doesn't justify the management focus.

One-time fire incident (Kadapa)

Low

September 2026 fire at Kadapa plant caused 34.4 Cr loss (one-time charge). Insured and claim lodged, but highlights operational/supply-chain concentration risk.

Management

Score 7/10. Clear on numbers and strategy. Transparent on cost environment challenges and margin pressure. Some evasion on brand performance details (EYRA/NEXIVUE contribution not quantified) and export strategy still vague ('too early to name geographies'). No significant NDA shields observed; candid on STOC certification status and competitive landscape. Track record of 'always over-delivered from guidance' per management (not independently verified). H1 FY27 revenue 3,148 Cr (89.7% growth) ahead of implied pace for 54-61% FY27 guidance. Housing enclosure plant on track for Q4 trials → Q1 commercial production. CapEx 650 Cr allocated and being deployed on schedule.

What to watch next
  • 1 · Q4 FY27

    CP PLUS PRO series rollout (premium enterprise segment targeting). Home IoT modules. Housing plant going live.

  • 2 · FY28

    Backward integration benefits accrue: cable plant live, housing enclosure volume, IoT lens production ramping. Margin floor expected to rise as vertical cost structure locks in.

  • 3 · Late FY2029–Early FY2030

    Capacity doubling complete (Kadapa phase 3 + Greater Noida). Two-million-per-month lens plant online. Supports 54-61% growth trajectory into FY28.

The risk is if SOC/memory costs don't stabilize as anticipated.

Informational and educational content only. Not investment advice.